Amarillo Biosciences, Inc. has entered a second license and supply agreement with CytoPharm, Inc. of Taiwan for Amarillo Biosciences’ low-dose interferon. Under this agreement, CytoPharma will conduct tests to support the use of low-dose interferon in animals (swine, poultry, cattle) to treat or prevent animal diseases. CytoPharm will seek approval of the drug in Taiwan and China. CytoPharm is already conducting a Phase II clinical trial to test whether low-dose interferon can prevent relapse in hepatitis C patients. More details...

Stock Symbol: (OTCBB: AMAR)